Key Points
Oct 30 (Reuters) - Belgiums drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO) popular obesity drug Wegovy, in which the injector pens contained insulin...
The Federal Agency for Medicines and Health Products told Reuters that this year it had detained nine mailed packages of GLP-1 medicines, the class of drugs that includes Wegovy and Novo's diabetes drug Ozempic, on the suspicion that they were fake...
Britain on Thursday warned the public about buying potentially fake weight-loss pens claiming to be Ozempic or Novo Nordisk's older weight-loss drug Saxenda after reports of a "very small number" of hospitalizations...
Belgiums health minister said last week the country wanted to temporarily ban the use of Ozempic as a weight loss treatment for a few weeks or months to deal with a shortage of the medicine, which is approved to treat type 2 diabetes, the original use for GLP-1 drugs...
Law enforcement, anti-counterfeiting and public health officials have said they are opening inquiries into complaints of fake drugs, trolling e-commerce and social media for purchase offers or advertisements, and training customs officials on how to spot counterfeits to help stem the surge...
You might be interested in
UK warns of fake Ozempic pens after hospitalisations
27, Oct, 23Britain on Thursday cautioned the public about buying fake weight-loss pens claiming to contain Novo Nordisk's diabetes drug Ozempic or weight-loss drug Saxenda after reports of a "very small number" of hospitalisations.
Swedish regulator asks doctors not to prescribe diabetes drugs for weight loss
11, Dec, 23Sweden's drugs agency on Monday asked doctors to hold off on prescribing diabetes drugs for the treatment of obesity, pointing to signs that a spike in such usage has left diabetics short of medication.
Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks
08, Aug, 23In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss but has also shown a remarkable reduction in the risk of heart disease.
Exclusive: WHO to consider adding obesity drugs to 'essential' medicines list
02, Apr, 23Drugs that combat obesity are under consideration for the first time for the World Health Organization's "essential medicines list," used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters.
The Obesity Drug Revolution Just Got Real
08, Aug, 23Wegovy reduces risk of heart attack, stroke in study, paving way for greater insurance coverage
EMA says no evidence GLP-1 drugs like Ozempic linked to thyroid cancer
27, Oct, 23The European Medicines Agency (EMA) on Friday said its safety panel did not find a causal link between popular GLP-1 drugs such as Novo Nordisk's (NOVOb.CO) Ozempic and thyroid cancer after a months-long review.
Analysis: Europe faces long wait for weight-loss drugs as governments eye costs
10, Jul, 23Novo Nordisk (NOVOb.CO) will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health insurance plans will be able to get it.
Weight loss drugs transforming healthcare, may help with addiction
09, Nov, 23A new class of weight loss drugs is transforming the U.S. healthcare system in ways that could extend to equally hard-to-treat areas like substance abuse, according to speakers at the Reuters Events Total Health conference in Chicago this week.
Launches of Novo Nordisk's weight-loss drug Wegovy
23, Nov, 23Novo Nordisk (NOVOb.CO) is pushing ahead with the launches of weight-loss drug Wegovy in Europe and Japan, even as it struggles to keep up with demand.
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
12, Jun, 23Two researchers whose work led to the development of Wegovy and Ozempic spoke to WIRED about the creation of these drugs and how they should be used.